Global Obesity Treatment

Obesity Treatment Comprehensive Study by Application (Children, Adults), Drugs (Combination Drugs, Appetite Suppressants, Malabsorption, Satiety), Treatment (Medication, Surgery, Lifestyle Changes), End-Users (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2030

Obesity Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 17.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Obesity Treatment
Obesity is a complex disorder state of being excessive fat. Various causes of Obesity disorder such as overeating, genetics, physical inactivity, psychological factors, engineered junk foods, unhealthy diet, medical problems, social and economic issues, pregnancy, lack of sleep, among others. In the last few years, the overweight patient has significantly increased. For instance, according to an article published by Health Metrics and Evaluation, more than 30.0% of the global population is either obese or overweight in 2014. Hence, rising number of overweight patients, growing awareness of health and treatments, augmented spending on healthcare and demand for treatments, among others are some of the major factors which affect the growth of the market in future.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia-Pacific
UnitValue (USD Million)
CAGR17.2%


The obesity treatment market is highly fragmented in nature with a large number of international as well as regional players such as VIVUS, Inc. (United States), Arena Pharmaceuticals, Inc. (United States), F. Hoffmann-La Roche, Ltd. (Switzerland), among others are operating in the market Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Obesity Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

VIVUS, Inc. (United States), Arena Pharmaceuticals, Inc. (United States), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (United States), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (United States) and Johnson & Johnson Services, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Medtronic (United States), USGI Medical, Inc. (United States), Mediflex Surgical Products (United States), Covidien plc (Ireland) and Olympus Corporation (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Obesity Treatment market by , Application (Children and Adults) and Region.



On the basis of geography, the market of Obesity Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Drugs, the sub-segment i.e. Combination Drugs will boost the Obesity Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Medication will boost the Obesity Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Users, the sub-segment i.e. Hospitals will boost the Obesity Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Disposable Income, Improving Healthcare Infrastructure, and the Emerging Medical Tourism Industry across the World

Market Growth Drivers:
Rising Healthcare Expenditure, and Encouraging Government Support for Research and Development and Rising Awareness of Adverse Health Effects Related to Overweight Weight Problems

Challenges:
Major Concern Regarding the Low Healthcare Expenditure in the Middle and Low-Income Countries Such as Africa

Restraints:
Issue Related to High Cost of Surgery Followed by the Risks of Infection and Anesthesia Allergy

Opportunities:
Growing Demand from Emerging Economics Market Such as China, India, Brazil, among others

In July 2017, the Novo Nordisk A/S (Denmark) Company has launched the anti-obesity drug in India, which is used for the treatment of obesity patients. Hence, this launched will benefit increase the product portfolio of the company


Key Target Audience
Pharmaceutical Companies, Biotechnological Institutes, Government and Private Laboratories, Research and Development (R&D) Companies, Medical Research Laboratories and Market Research and Consulting Service Providers

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Children
  • Adults
By Drugs
  • Combination Drugs
  • Appetite Suppressants
  • Malabsorption
  • Satiety

By Treatment
  • Medication
  • Surgery
  • Lifestyle Changes

By End-Users
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Healthcare Expenditure, and Encouraging Government Support for Research and Development
      • 3.2.2. Rising Awareness of Adverse Health Effects Related to Overweight Weight Problems
    • 3.3. Market Challenges
      • 3.3.1. Major Concern Regarding the Low Healthcare Expenditure in the Middle and Low-Income Countries Such as Africa
    • 3.4. Market Trends
      • 3.4.1. Growing Disposable Income, Improving Healthcare Infrastructure, and the Emerging Medical Tourism Industry across the World
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Obesity Treatment, by Application, Drugs, Treatment, End-Users and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Obesity Treatment (Value)
      • 5.2.1. Global Obesity Treatment by: Application (Value)
        • 5.2.1.1. Children
        • 5.2.1.2. Adults
      • 5.2.2. Global Obesity Treatment by: Drugs (Value)
        • 5.2.2.1. Combination Drugs
        • 5.2.2.2. Appetite Suppressants
        • 5.2.2.3. Malabsorption
        • 5.2.2.4. Satiety
      • 5.2.3. Global Obesity Treatment by: Treatment (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. Surgery
        • 5.2.3.3. Lifestyle Changes
      • 5.2.4. Global Obesity Treatment by: End-Users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Obesity Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Obesity Treatment (Volume)
      • 5.3.1. Global Obesity Treatment by: Application (Volume)
        • 5.3.1.1. Children
        • 5.3.1.2. Adults
      • 5.3.2. Global Obesity Treatment by: Drugs (Volume)
        • 5.3.2.1. Combination Drugs
        • 5.3.2.2. Appetite Suppressants
        • 5.3.2.3. Malabsorption
        • 5.3.2.4. Satiety
      • 5.3.3. Global Obesity Treatment by: Treatment (Volume)
        • 5.3.3.1. Medication
        • 5.3.3.2. Surgery
        • 5.3.3.3. Lifestyle Changes
      • 5.3.4. Global Obesity Treatment by: End-Users (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Others
      • 5.3.5. Global Obesity Treatment Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Obesity Treatment (Price)
  • 6. Obesity Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. VIVUS, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Arena Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche, Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novo Nordisk A/S (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Orexigen Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Allergan (Republic of Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cousin Biotech (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. EnteroMedics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson Services, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Obesity Treatment Sale, by Application, Drugs, Treatment, End-Users and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Obesity Treatment (Value)
      • 7.2.1. Global Obesity Treatment by: Application (Value)
        • 7.2.1.1. Children
        • 7.2.1.2. Adults
      • 7.2.2. Global Obesity Treatment by: Drugs (Value)
        • 7.2.2.1. Combination Drugs
        • 7.2.2.2. Appetite Suppressants
        • 7.2.2.3. Malabsorption
        • 7.2.2.4. Satiety
      • 7.2.3. Global Obesity Treatment by: Treatment (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. Surgery
        • 7.2.3.3. Lifestyle Changes
      • 7.2.4. Global Obesity Treatment by: End-Users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Obesity Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Obesity Treatment (Volume)
      • 7.3.1. Global Obesity Treatment by: Application (Volume)
        • 7.3.1.1. Children
        • 7.3.1.2. Adults
      • 7.3.2. Global Obesity Treatment by: Drugs (Volume)
        • 7.3.2.1. Combination Drugs
        • 7.3.2.2. Appetite Suppressants
        • 7.3.2.3. Malabsorption
        • 7.3.2.4. Satiety
      • 7.3.3. Global Obesity Treatment by: Treatment (Volume)
        • 7.3.3.1. Medication
        • 7.3.3.2. Surgery
        • 7.3.3.3. Lifestyle Changes
      • 7.3.4. Global Obesity Treatment by: End-Users (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Others
      • 7.3.5. Global Obesity Treatment Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Obesity Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Obesity Treatment: by Application(USD Million)
  • Table 2. Obesity Treatment Children , by Region USD Million (2018-2023)
  • Table 3. Obesity Treatment Adults , by Region USD Million (2018-2023)
  • Table 4. Obesity Treatment: by Drugs(USD Million)
  • Table 5. Obesity Treatment Combination Drugs , by Region USD Million (2018-2023)
  • Table 6. Obesity Treatment Appetite Suppressants , by Region USD Million (2018-2023)
  • Table 7. Obesity Treatment Malabsorption , by Region USD Million (2018-2023)
  • Table 8. Obesity Treatment Satiety , by Region USD Million (2018-2023)
  • Table 9. Obesity Treatment: by Treatment(USD Million)
  • Table 10. Obesity Treatment Medication , by Region USD Million (2018-2023)
  • Table 11. Obesity Treatment Surgery , by Region USD Million (2018-2023)
  • Table 12. Obesity Treatment Lifestyle Changes , by Region USD Million (2018-2023)
  • Table 13. Obesity Treatment: by End-Users(USD Million)
  • Table 14. Obesity Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 15. Obesity Treatment Clinics , by Region USD Million (2018-2023)
  • Table 16. Obesity Treatment Others , by Region USD Million (2018-2023)
  • Table 17. South America Obesity Treatment, by Country USD Million (2018-2023)
  • Table 18. South America Obesity Treatment, by Application USD Million (2018-2023)
  • Table 19. South America Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 20. South America Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 21. South America Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 22. Brazil Obesity Treatment, by Application USD Million (2018-2023)
  • Table 23. Brazil Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 24. Brazil Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 25. Brazil Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 26. Argentina Obesity Treatment, by Application USD Million (2018-2023)
  • Table 27. Argentina Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 28. Argentina Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 29. Argentina Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 30. Rest of South America Obesity Treatment, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 32. Rest of South America Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 33. Rest of South America Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 34. Asia Pacific Obesity Treatment, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Obesity Treatment, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 37. Asia Pacific Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 38. Asia Pacific Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 39. China Obesity Treatment, by Application USD Million (2018-2023)
  • Table 40. China Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 41. China Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 42. China Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 43. Japan Obesity Treatment, by Application USD Million (2018-2023)
  • Table 44. Japan Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 45. Japan Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 46. Japan Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 47. India Obesity Treatment, by Application USD Million (2018-2023)
  • Table 48. India Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 49. India Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 50. India Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 51. South Korea Obesity Treatment, by Application USD Million (2018-2023)
  • Table 52. South Korea Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 53. South Korea Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 54. South Korea Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 55. Taiwan Obesity Treatment, by Application USD Million (2018-2023)
  • Table 56. Taiwan Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 57. Taiwan Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 58. Taiwan Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 59. Australia Obesity Treatment, by Application USD Million (2018-2023)
  • Table 60. Australia Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 61. Australia Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 62. Australia Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Obesity Treatment, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 67. Europe Obesity Treatment, by Country USD Million (2018-2023)
  • Table 68. Europe Obesity Treatment, by Application USD Million (2018-2023)
  • Table 69. Europe Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 70. Europe Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 71. Europe Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 72. Germany Obesity Treatment, by Application USD Million (2018-2023)
  • Table 73. Germany Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 74. Germany Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 75. Germany Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 76. France Obesity Treatment, by Application USD Million (2018-2023)
  • Table 77. France Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 78. France Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 79. France Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 80. Italy Obesity Treatment, by Application USD Million (2018-2023)
  • Table 81. Italy Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 82. Italy Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 83. Italy Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 84. United Kingdom Obesity Treatment, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 86. United Kingdom Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 87. United Kingdom Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 88. Netherlands Obesity Treatment, by Application USD Million (2018-2023)
  • Table 89. Netherlands Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 90. Netherlands Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 91. Netherlands Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 92. Rest of Europe Obesity Treatment, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 94. Rest of Europe Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 95. Rest of Europe Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 96. MEA Obesity Treatment, by Country USD Million (2018-2023)
  • Table 97. MEA Obesity Treatment, by Application USD Million (2018-2023)
  • Table 98. MEA Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 99. MEA Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 100. MEA Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 101. Middle East Obesity Treatment, by Application USD Million (2018-2023)
  • Table 102. Middle East Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 103. Middle East Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 104. Middle East Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 105. Africa Obesity Treatment, by Application USD Million (2018-2023)
  • Table 106. Africa Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 107. Africa Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 108. Africa Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 109. North America Obesity Treatment, by Country USD Million (2018-2023)
  • Table 110. North America Obesity Treatment, by Application USD Million (2018-2023)
  • Table 111. North America Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 112. North America Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 113. North America Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 114. United States Obesity Treatment, by Application USD Million (2018-2023)
  • Table 115. United States Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 116. United States Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 117. United States Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 118. Canada Obesity Treatment, by Application USD Million (2018-2023)
  • Table 119. Canada Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 120. Canada Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 121. Canada Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 122. Mexico Obesity Treatment, by Application USD Million (2018-2023)
  • Table 123. Mexico Obesity Treatment, by Drugs USD Million (2018-2023)
  • Table 124. Mexico Obesity Treatment, by Treatment USD Million (2018-2023)
  • Table 125. Mexico Obesity Treatment, by End-Users USD Million (2018-2023)
  • Table 126. Obesity Treatment Sales: by Application(k Tons)
  • Table 127. Obesity Treatment Sales Children , by Region k Tons (2018-2023)
  • Table 128. Obesity Treatment Sales Adults , by Region k Tons (2018-2023)
  • Table 129. Obesity Treatment Sales: by Drugs(k Tons)
  • Table 130. Obesity Treatment Sales Combination Drugs , by Region k Tons (2018-2023)
  • Table 131. Obesity Treatment Sales Appetite Suppressants , by Region k Tons (2018-2023)
  • Table 132. Obesity Treatment Sales Malabsorption , by Region k Tons (2018-2023)
  • Table 133. Obesity Treatment Sales Satiety , by Region k Tons (2018-2023)
  • Table 134. Obesity Treatment Sales: by Treatment(k Tons)
  • Table 135. Obesity Treatment Sales Medication , by Region k Tons (2018-2023)
  • Table 136. Obesity Treatment Sales Surgery , by Region k Tons (2018-2023)
  • Table 137. Obesity Treatment Sales Lifestyle Changes , by Region k Tons (2018-2023)
  • Table 138. Obesity Treatment Sales: by End-Users(k Tons)
  • Table 139. Obesity Treatment Sales Hospitals , by Region k Tons (2018-2023)
  • Table 140. Obesity Treatment Sales Clinics , by Region k Tons (2018-2023)
  • Table 141. Obesity Treatment Sales Others , by Region k Tons (2018-2023)
  • Table 142. South America Obesity Treatment Sales, by Country k Tons (2018-2023)
  • Table 143. South America Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 144. South America Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 145. South America Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 146. South America Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 147. Brazil Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 148. Brazil Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 149. Brazil Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 150. Brazil Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 151. Argentina Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 152. Argentina Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 153. Argentina Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 154. Argentina Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 155. Rest of South America Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 156. Rest of South America Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 157. Rest of South America Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 158. Rest of South America Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 159. Asia Pacific Obesity Treatment Sales, by Country k Tons (2018-2023)
  • Table 160. Asia Pacific Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 161. Asia Pacific Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 162. Asia Pacific Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 163. Asia Pacific Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 164. China Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 165. China Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 166. China Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 167. China Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 168. Japan Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 169. Japan Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 170. Japan Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 171. Japan Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 172. India Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 173. India Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 174. India Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 175. India Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 176. South Korea Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 177. South Korea Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 178. South Korea Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 179. South Korea Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 180. Taiwan Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 181. Taiwan Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 182. Taiwan Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 183. Taiwan Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 184. Australia Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 185. Australia Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 186. Australia Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 187. Australia Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 188. Rest of Asia-Pacific Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 189. Rest of Asia-Pacific Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 190. Rest of Asia-Pacific Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 191. Rest of Asia-Pacific Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 192. Europe Obesity Treatment Sales, by Country k Tons (2018-2023)
  • Table 193. Europe Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 194. Europe Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 195. Europe Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 196. Europe Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 197. Germany Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 198. Germany Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 199. Germany Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 200. Germany Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 201. France Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 202. France Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 203. France Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 204. France Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 205. Italy Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 206. Italy Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 207. Italy Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 208. Italy Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 209. United Kingdom Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 210. United Kingdom Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 211. United Kingdom Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 212. United Kingdom Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 213. Netherlands Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 214. Netherlands Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 215. Netherlands Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 216. Netherlands Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 217. Rest of Europe Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 218. Rest of Europe Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 219. Rest of Europe Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 220. Rest of Europe Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 221. MEA Obesity Treatment Sales, by Country k Tons (2018-2023)
  • Table 222. MEA Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 223. MEA Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 224. MEA Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 225. MEA Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 226. Middle East Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 227. Middle East Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 228. Middle East Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 229. Middle East Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 230. Africa Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 231. Africa Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 232. Africa Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 233. Africa Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 234. North America Obesity Treatment Sales, by Country k Tons (2018-2023)
  • Table 235. North America Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 236. North America Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 237. North America Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 238. North America Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 239. United States Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 240. United States Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 241. United States Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 242. United States Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 243. Canada Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 244. Canada Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 245. Canada Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 246. Canada Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 247. Mexico Obesity Treatment Sales, by Application k Tons (2018-2023)
  • Table 248. Mexico Obesity Treatment Sales, by Drugs k Tons (2018-2023)
  • Table 249. Mexico Obesity Treatment Sales, by Treatment k Tons (2018-2023)
  • Table 250. Mexico Obesity Treatment Sales, by End-Users k Tons (2018-2023)
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Obesity Treatment: by Application(USD Million)
  • Table 261. Obesity Treatment Children , by Region USD Million (2025-2030)
  • Table 262. Obesity Treatment Adults , by Region USD Million (2025-2030)
  • Table 263. Obesity Treatment: by Drugs(USD Million)
  • Table 264. Obesity Treatment Combination Drugs , by Region USD Million (2025-2030)
  • Table 265. Obesity Treatment Appetite Suppressants , by Region USD Million (2025-2030)
  • Table 266. Obesity Treatment Malabsorption , by Region USD Million (2025-2030)
  • Table 267. Obesity Treatment Satiety , by Region USD Million (2025-2030)
  • Table 268. Obesity Treatment: by Treatment(USD Million)
  • Table 269. Obesity Treatment Medication , by Region USD Million (2025-2030)
  • Table 270. Obesity Treatment Surgery , by Region USD Million (2025-2030)
  • Table 271. Obesity Treatment Lifestyle Changes , by Region USD Million (2025-2030)
  • Table 272. Obesity Treatment: by End-Users(USD Million)
  • Table 273. Obesity Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 274. Obesity Treatment Clinics , by Region USD Million (2025-2030)
  • Table 275. Obesity Treatment Others , by Region USD Million (2025-2030)
  • Table 276. South America Obesity Treatment, by Country USD Million (2025-2030)
  • Table 277. South America Obesity Treatment, by Application USD Million (2025-2030)
  • Table 278. South America Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 279. South America Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 280. South America Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 281. Brazil Obesity Treatment, by Application USD Million (2025-2030)
  • Table 282. Brazil Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 283. Brazil Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 284. Brazil Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 285. Argentina Obesity Treatment, by Application USD Million (2025-2030)
  • Table 286. Argentina Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 287. Argentina Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 288. Argentina Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 289. Rest of South America Obesity Treatment, by Application USD Million (2025-2030)
  • Table 290. Rest of South America Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 291. Rest of South America Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 292. Rest of South America Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 293. Asia Pacific Obesity Treatment, by Country USD Million (2025-2030)
  • Table 294. Asia Pacific Obesity Treatment, by Application USD Million (2025-2030)
  • Table 295. Asia Pacific Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 296. Asia Pacific Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 297. Asia Pacific Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 298. China Obesity Treatment, by Application USD Million (2025-2030)
  • Table 299. China Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 300. China Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 301. China Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 302. Japan Obesity Treatment, by Application USD Million (2025-2030)
  • Table 303. Japan Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 304. Japan Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 305. Japan Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 306. India Obesity Treatment, by Application USD Million (2025-2030)
  • Table 307. India Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 308. India Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 309. India Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 310. South Korea Obesity Treatment, by Application USD Million (2025-2030)
  • Table 311. South Korea Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 312. South Korea Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 313. South Korea Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 314. Taiwan Obesity Treatment, by Application USD Million (2025-2030)
  • Table 315. Taiwan Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 316. Taiwan Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 317. Taiwan Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 318. Australia Obesity Treatment, by Application USD Million (2025-2030)
  • Table 319. Australia Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 320. Australia Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 321. Australia Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 322. Rest of Asia-Pacific Obesity Treatment, by Application USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 326. Europe Obesity Treatment, by Country USD Million (2025-2030)
  • Table 327. Europe Obesity Treatment, by Application USD Million (2025-2030)
  • Table 328. Europe Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 329. Europe Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 330. Europe Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 331. Germany Obesity Treatment, by Application USD Million (2025-2030)
  • Table 332. Germany Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 333. Germany Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 334. Germany Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 335. France Obesity Treatment, by Application USD Million (2025-2030)
  • Table 336. France Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 337. France Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 338. France Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 339. Italy Obesity Treatment, by Application USD Million (2025-2030)
  • Table 340. Italy Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 341. Italy Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 342. Italy Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 343. United Kingdom Obesity Treatment, by Application USD Million (2025-2030)
  • Table 344. United Kingdom Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 345. United Kingdom Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 346. United Kingdom Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 347. Netherlands Obesity Treatment, by Application USD Million (2025-2030)
  • Table 348. Netherlands Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 349. Netherlands Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 350. Netherlands Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 351. Rest of Europe Obesity Treatment, by Application USD Million (2025-2030)
  • Table 352. Rest of Europe Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 353. Rest of Europe Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 354. Rest of Europe Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 355. MEA Obesity Treatment, by Country USD Million (2025-2030)
  • Table 356. MEA Obesity Treatment, by Application USD Million (2025-2030)
  • Table 357. MEA Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 358. MEA Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 359. MEA Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 360. Middle East Obesity Treatment, by Application USD Million (2025-2030)
  • Table 361. Middle East Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 362. Middle East Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 363. Middle East Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 364. Africa Obesity Treatment, by Application USD Million (2025-2030)
  • Table 365. Africa Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 366. Africa Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 367. Africa Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 368. North America Obesity Treatment, by Country USD Million (2025-2030)
  • Table 369. North America Obesity Treatment, by Application USD Million (2025-2030)
  • Table 370. North America Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 371. North America Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 372. North America Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 373. United States Obesity Treatment, by Application USD Million (2025-2030)
  • Table 374. United States Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 375. United States Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 376. United States Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 377. Canada Obesity Treatment, by Application USD Million (2025-2030)
  • Table 378. Canada Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 379. Canada Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 380. Canada Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 381. Mexico Obesity Treatment, by Application USD Million (2025-2030)
  • Table 382. Mexico Obesity Treatment, by Drugs USD Million (2025-2030)
  • Table 383. Mexico Obesity Treatment, by Treatment USD Million (2025-2030)
  • Table 384. Mexico Obesity Treatment, by End-Users USD Million (2025-2030)
  • Table 385. Obesity Treatment Sales: by Application(k Tons)
  • Table 386. Obesity Treatment Sales Children , by Region k Tons (2025-2030)
  • Table 387. Obesity Treatment Sales Adults , by Region k Tons (2025-2030)
  • Table 388. Obesity Treatment Sales: by Drugs(k Tons)
  • Table 389. Obesity Treatment Sales Combination Drugs , by Region k Tons (2025-2030)
  • Table 390. Obesity Treatment Sales Appetite Suppressants , by Region k Tons (2025-2030)
  • Table 391. Obesity Treatment Sales Malabsorption , by Region k Tons (2025-2030)
  • Table 392. Obesity Treatment Sales Satiety , by Region k Tons (2025-2030)
  • Table 393. Obesity Treatment Sales: by Treatment(k Tons)
  • Table 394. Obesity Treatment Sales Medication , by Region k Tons (2025-2030)
  • Table 395. Obesity Treatment Sales Surgery , by Region k Tons (2025-2030)
  • Table 396. Obesity Treatment Sales Lifestyle Changes , by Region k Tons (2025-2030)
  • Table 397. Obesity Treatment Sales: by End-Users(k Tons)
  • Table 398. Obesity Treatment Sales Hospitals , by Region k Tons (2025-2030)
  • Table 399. Obesity Treatment Sales Clinics , by Region k Tons (2025-2030)
  • Table 400. Obesity Treatment Sales Others , by Region k Tons (2025-2030)
  • Table 401. South America Obesity Treatment Sales, by Country k Tons (2025-2030)
  • Table 402. South America Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 403. South America Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 404. South America Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 405. South America Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 406. Brazil Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 407. Brazil Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 408. Brazil Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 409. Brazil Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 410. Argentina Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 411. Argentina Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 412. Argentina Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 413. Argentina Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 414. Rest of South America Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 415. Rest of South America Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 416. Rest of South America Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 417. Rest of South America Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 418. Asia Pacific Obesity Treatment Sales, by Country k Tons (2025-2030)
  • Table 419. Asia Pacific Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 420. Asia Pacific Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 421. Asia Pacific Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 422. Asia Pacific Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 423. China Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 424. China Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 425. China Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 426. China Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 427. Japan Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 428. Japan Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 429. Japan Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 430. Japan Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 431. India Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 432. India Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 433. India Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 434. India Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 435. South Korea Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 436. South Korea Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 437. South Korea Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 438. South Korea Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 439. Taiwan Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 440. Taiwan Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 441. Taiwan Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 442. Taiwan Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 443. Australia Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 444. Australia Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 445. Australia Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 446. Australia Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 447. Rest of Asia-Pacific Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 448. Rest of Asia-Pacific Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 449. Rest of Asia-Pacific Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 450. Rest of Asia-Pacific Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 451. Europe Obesity Treatment Sales, by Country k Tons (2025-2030)
  • Table 452. Europe Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 453. Europe Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 454. Europe Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 455. Europe Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 456. Germany Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 457. Germany Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 458. Germany Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 459. Germany Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 460. France Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 461. France Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 462. France Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 463. France Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 464. Italy Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 465. Italy Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 466. Italy Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 467. Italy Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 468. United Kingdom Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 469. United Kingdom Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 470. United Kingdom Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 471. United Kingdom Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 472. Netherlands Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 473. Netherlands Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 474. Netherlands Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 475. Netherlands Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 476. Rest of Europe Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 477. Rest of Europe Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 478. Rest of Europe Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 479. Rest of Europe Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 480. MEA Obesity Treatment Sales, by Country k Tons (2025-2030)
  • Table 481. MEA Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 482. MEA Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 483. MEA Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 484. MEA Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 485. Middle East Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 486. Middle East Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 487. Middle East Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 488. Middle East Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 489. Africa Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 490. Africa Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 491. Africa Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 492. Africa Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 493. North America Obesity Treatment Sales, by Country k Tons (2025-2030)
  • Table 494. North America Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 495. North America Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 496. North America Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 497. North America Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 498. United States Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 499. United States Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 500. United States Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 501. United States Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 502. Canada Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 503. Canada Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 504. Canada Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 505. Canada Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 506. Mexico Obesity Treatment Sales, by Application k Tons (2025-2030)
  • Table 507. Mexico Obesity Treatment Sales, by Drugs k Tons (2025-2030)
  • Table 508. Mexico Obesity Treatment Sales, by Treatment k Tons (2025-2030)
  • Table 509. Mexico Obesity Treatment Sales, by End-Users k Tons (2025-2030)
  • Table 510. Research Programs/Design for This Report
  • Table 511. Key Data Information from Secondary Sources
  • Table 512. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Obesity Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Obesity Treatment: by Drugs USD Million (2018-2023)
  • Figure 6. Global Obesity Treatment: by Treatment USD Million (2018-2023)
  • Figure 7. Global Obesity Treatment: by End-Users USD Million (2018-2023)
  • Figure 8. South America Obesity Treatment Share (%), by Country
  • Figure 9. Asia Pacific Obesity Treatment Share (%), by Country
  • Figure 10. Europe Obesity Treatment Share (%), by Country
  • Figure 11. MEA Obesity Treatment Share (%), by Country
  • Figure 12. North America Obesity Treatment Share (%), by Country
  • Figure 13. Global Obesity Treatment: by Application k Tons (2018-2023)
  • Figure 14. Global Obesity Treatment: by Drugs k Tons (2018-2023)
  • Figure 15. Global Obesity Treatment: by Treatment k Tons (2018-2023)
  • Figure 16. Global Obesity Treatment: by End-Users k Tons (2018-2023)
  • Figure 17. South America Obesity Treatment Share (%), by Country
  • Figure 18. Asia Pacific Obesity Treatment Share (%), by Country
  • Figure 19. Europe Obesity Treatment Share (%), by Country
  • Figure 20. MEA Obesity Treatment Share (%), by Country
  • Figure 21. North America Obesity Treatment Share (%), by Country
  • Figure 22. Global Obesity Treatment share by Players 2023 (%)
  • Figure 23. Global Obesity Treatment share by Players (Top 3) 2023(%)
  • Figure 24. Global Obesity Treatment share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. VIVUS, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. VIVUS, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Arena Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Arena Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. F. Hoffmann-La Roche, Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche, Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 32. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 33. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 34. Orexigen Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Orexigen Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Allergan (Republic of Ireland) Revenue, Net Income and Gross profit
  • Figure 37. Allergan (Republic of Ireland) Revenue: by Geography 2023
  • Figure 38. Cousin Biotech (France) Revenue, Net Income and Gross profit
  • Figure 39. Cousin Biotech (France) Revenue: by Geography 2023
  • Figure 40. EnteroMedics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. EnteroMedics, Inc. (United States) Revenue: by Geography 2023
  • Figure 42. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 44. Global Obesity Treatment: by Application USD Million (2025-2030)
  • Figure 45. Global Obesity Treatment: by Drugs USD Million (2025-2030)
  • Figure 46. Global Obesity Treatment: by Treatment USD Million (2025-2030)
  • Figure 47. Global Obesity Treatment: by End-Users USD Million (2025-2030)
  • Figure 48. South America Obesity Treatment Share (%), by Country
  • Figure 49. Asia Pacific Obesity Treatment Share (%), by Country
  • Figure 50. Europe Obesity Treatment Share (%), by Country
  • Figure 51. MEA Obesity Treatment Share (%), by Country
  • Figure 52. North America Obesity Treatment Share (%), by Country
  • Figure 53. Global Obesity Treatment: by Application k Tons (2025-2030)
  • Figure 54. Global Obesity Treatment: by Drugs k Tons (2025-2030)
  • Figure 55. Global Obesity Treatment: by Treatment k Tons (2025-2030)
  • Figure 56. Global Obesity Treatment: by End-Users k Tons (2025-2030)
  • Figure 57. South America Obesity Treatment Share (%), by Country
  • Figure 58. Asia Pacific Obesity Treatment Share (%), by Country
  • Figure 59. Europe Obesity Treatment Share (%), by Country
  • Figure 60. MEA Obesity Treatment Share (%), by Country
  • Figure 61. North America Obesity Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • VIVUS, Inc. (United States)
  • Arena Pharmaceuticals, Inc. (United States)
  • F. Hoffmann-La Roche, Ltd. (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Orexigen Therapeutics, Inc. (United States)
  • Allergan (Republic of Ireland)
  • Cousin Biotech (France)
  • EnteroMedics, Inc. (United States)
  • Johnson & Johnson Services, Inc. (United States)
Additional players considered in the study are as follows:
Medtronic (United States) , USGI Medical, Inc. (United States) , Mediflex Surgical Products (United States) , Covidien plc (Ireland) , Olympus Corporation (Japan)
Select User Access Type

Key Highlights of Report


Apr 2024 138 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Obesity Treatment Quantitative research analysis
Global Obesity Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as VIVUS, Inc. (United States), Arena Pharmaceuticals, Inc. (United States), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (United States), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (United States) and Johnson & Johnson Services, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Disposable Income, Improving Healthcare Infrastructure, and the Emerging Medical Tourism Industry across the World" is seen as one of major influencing trends for Obesity Treatment Market during projected period 2023-2030.
The Obesity Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Obesity Treatment Report?

Have a Query? Click Here

Other Related Reports

Plant Sterol Esters Comprehensive Study by Type (Oil, Powder), End Users (Food & Beverages, Dairy Products, Pharmaceutical, Cosmetics) Players and Region - Global Market Outlook to 2026
$ 3500
Companion Diagnostics Comprehensive Study by End-users (Pharma Companies, Reference Laboratories, CRO, Others), Product & Service (Assay kits & Reagents, Software & Services), Technology Type (Polyme...
$ 3750
Vaccines & Vaccination Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Application (Pediatrics disease, Adults disease), Route of Administration (Intramuscular and Subcutaneo...
$ 3750
Dog Calcium Supplement Comprehensive Study by Application (Households, Veterinary Hospitals, Pet Cannels, Other), Form (Powder, Paste, Liquid, Capsules, Other), Distribution Channel (Online, Offline)...
$ 3800
Quinine Sulphate Comprehensive Study by Application (Malaria, Problematic Leg Cramps, Other), Distribution Chanel (Online, Offline), Dose (200mg, 300mg, Other) Players and Region - Global Market Outl...
$ 3500
Ear Drops Comprehensive Study by Type (Antibiotic Ear Drops, Corticosteroid Ear Drops, Antifungal Ear Drops, Acidic Ear Drops), Application (Adult, Children), Composition (Ciprofloxacin, Dexamethason...
$ 3650